Funder: European Commission
Due Dates: January 27, 2026 (cut-off 1) | June 17, 2026 (cut-off 2) | September 4, 2026 (end of rebuttal stage)
Funding Amounts: Total funding available: €32,190,000; typical project duration: up to 48 months.
Summary: Funds collaborative, multi-country clinical trials on cardiovascular, autoimmune, and metabolic diseases, emphasizing comparative-effectiveness and drug repurposing studies in Europe.
Key Information: Minimum 3, maximum 5 countries per consortium; strict national eligibility rules apply.